IDEXX Laboratories (IDXX) is back in focus after third quarter results and a guidance update that pointed to higher full year revenue, earnings and reported EPS growth expectations for 2026.
The latest guidance upgrade has arrived alongside a sharp swing in sentiment around IDEXX Laboratories, with a 30 day share price return of 35.03% and a 90 day gain of 27.52% helping lift the stock to US$702.59. That rapid move comes alongside a much flatter 1 year total shareholder return of 0.16%. This suggests the recent earnings beat and higher full year expectations have only just started to reset how the market is pricing the company’s growth and risk profile.
Scan other fast-moving veterinary and healthcare diagnostics stocks showing strong earnings trends using our hand-picked 37 healthcare AI stocks for comparison against IDEXX Laboratories.
The share price reset has been fierce for IDEXX Laboratories, yet full year guidance only nudged higher. Is most of the rerating already in the rearview mirror, or does valuation still leave room for more?
Most Popular Narrative: 2% Undervalued
On the analyst consensus Narrative on Simply Wall St, IDEXX Laboratories screens as slightly undervalued, with a fair value of about $717 versus the last close at $702.59. This frames the recent rally as still just shy of that implied level.
The main factor that has to go right is that IDEXX Laboratories converts underpenetrated veterinary diagnostics demand into higher bloodwork inclusion and utilization across an expanding VetLab and inVue Dx installed base, even with softer clinical visit trends.
The current numbers and guidance imply a share price that already reflects solid execution, yet still allows for potential upside if the company delivers on its long-term algorithm while the stock is viewed as undervalued in this narrative’s assessment.
See why 31 investors see IDEXX Laboratories as 2% undervalued.
Result: Fair Value of $717.17 (UNDERVALUED)
Still, if U.S. vet visits stay weak or IDEXX Laboratories spends heavily on expansion without matching recurring diagnostics growth, this slightly undervalued narrative can quickly lose support.
Find out about the key risks to this IDEXX Laboratories narrative.
Another View: IDEXX Laboratories Looks Expensive On Earnings
The first narrative paints IDEXX Laboratories as modestly undervalued. A plain P/E check tells a different story. At 46.8x earnings versus a peer average of 34.6x and a fair ratio of 32.3x, buyers today are paying a clear premium. That premium may matter if growth expectations soften.
Before leaning too hard on the slight undervaluation call from the fair value narrative, it is worth asking whether this richer earnings multiple leaves less room for error or simply reflects quality that the market is willing to pay for, and how you feel about that trade off at this price point. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on valuation and risk around IDEXX Laboratories are clear already, so move quickly to inspect the full data and form your own stance with the 2 key rewards and 1 important warning sign.
Looking for more IDEXX Laboratories style investment ideas?
Do not stop your research with IDEXX Laboratories alone. Broaden your watchlist with other clear, data backed opportunities that could sharpen how you position your portfolio.
- Target quality at a discount by scanning companies that screen as attractively priced on fundamentals with the 32 high quality undervalued stocks.
- Strengthen your income stream by focusing on dependable payers using the 6 dividend fortresses.
- Reduce potential shocks by concentrating on financially resilient businesses through the 30 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com